Systems Medicine LLC Release: Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin
4/21/2009 9:53:22 AM
More...
|
Systems Medicine LLC Uses OmniComm Systems, Inc. (OMCM) for Electronic Data Capture (EDC) in a Phase II Oncology Study
8/21/2008 9:10:10 AM
More...
|
Systems Medicine LLC New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit Cancer
4/14/2008 10:05:02 AM
More...
|
Pharmatech, Inc. Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
3/3/2008 9:46:45 AM
More...
|
Systems Medicine Study Shows Brostallicin in Combination with Cisplatin is Well-Tolerated and Produces Prolonged Disease Stabilization in Patients with Platinum-Resistant Cancers
9/27/2007 11:06:52 AM
More...
|
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTIC), Announces Execution of CRADA with National Cancer Institute / National Institutes of Health (NIH) to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8/22/2007 9:07:24 AM
More...
|